NCT00141414已完成2 期
Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 82
- 试验地点
- 26
- 主要终点
- Safety
研究概览
简要总结
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have met the inclusion criteria for preceding double-blind study.
- •Have received double-blind study medication and wish to receive open-label pregabalin.
排除标准
- •Pregnant or considering becoming pregnant.
- •Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.
结局指标
主要结局
Safety
次要结局
未报告次要终点
研究者
研究点 (26)
Loading locations...
相似试验
已完成
3 期
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial SeizuresSeizure Disorder, PartialNCT00141388Pfizer455
已完成
3 期
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00150293Pfizer337
已完成
3 期
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00141336Pfizer750
已完成
3 期
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00141245Pfizer325
已完成
3 期
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral NeuropathyDiabetic Neuropathy, PainfulNCT00553280Pfizer's Upjohn has merged with Mylan to form Viatris Inc.123